Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2010
12/07/2010US7846477 Method for producing solid galenic formulations using a crosslinked non-thermoplastic carrier
12/07/2010US7846476 Once-a-day oxycodone formulations
12/07/2010US7846475 Soft capsules
12/07/2010US7846474 Administering a bisphosphonate until the bone mineral density is within a normal range, interrupting administration to enable the development of the sectional momentum of inertia, and resuming administration when the bone mineral density falls by 5-10% of the normal range
12/07/2010US7846473 Irinotecan preparation
12/07/2010US7846472 A mixture of propylene carbonate and glycerol formal in a ratio of 90:10-10:90 containing hydroxypropylmethylcellulose, a phospholipid and a fungicide; time-released agent; sustained'release; veterinary medicine; sustained release; topical, otic, and ophthalmic
12/07/2010US7846469 Reversible inhibition of sperm receptor synthesis for contraception
12/07/2010US7846468 Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
12/07/2010US7846451 Chimeric outermembrane polypeptide for use as tool in diagnosis and treatment of parasitic infection
12/07/2010US7846442 Methods of treating rheumatoid arthritis with an anti-TNF-alpha antibodies and methotrexate
12/07/2010US7846441 Treatment with anti-ErbB2 antibodies
12/07/2010US7846435 Humanized antibodies that recognize Verotoxin II and cell line producing same
12/07/2010US7846433 Methods of treating pre-eclampsia and eclampsia
12/07/2010US7846429 Compositions and methods for elimination of unwanted cells
12/07/2010US7846426 Using poloxamer; therapy for cardiovascular disorders, muscular dystrophy, apoptosis and antiischemic agents
12/07/2010US7846425 high shear nonaqueous granulation; treating renal disease; sevelamer is polyallylamine-epichlorohydrin copolymer and binds phosphate; tablet form
12/07/2010US7846422 Administering a lignan comprising 4-(phenyl)-furo/3*,4*:6,7/-naphtho/2,3-d/-1,3-dioxole derivative or plant extract
12/07/2010US7846411 combine both whitening/stain removal of teeth with remineralization; calcium peroxyphosphate compounds are capable of releasing, in an aqueous environment, whitening and remineralization effective amounts of calcium ion, phosphate ion, and active oxygen; calcium peroxymonophosphate
12/07/2010CA2616449C Compositions for external application, containing adenosyl cobalamin for improvement of skin diseases
12/07/2010CA2592605C Method for stabilizing anti-dementia drug
12/07/2010CA2588662C New 3-phenylpropionic acid derivatives for the treatment of diabetes
12/07/2010CA2583084C 7,8-bicycloalkyl-chroman derivatives
12/07/2010CA2577430C 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione and analogues as inhibitors of macrophage elastase
12/07/2010CA2573201C Injection of a radioactive dye for sentinel lymph node identification
12/07/2010CA2560221C Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
12/07/2010CA2552318C Composition for combating ectoparasites and their ova
12/07/2010CA2540248C Resolution of a narwedine amide derivative
12/07/2010CA2492260C Prostaglandin derivatives
12/07/2010CA2488334C 24-sulfoximine vitamin d3 compounds
12/07/2010CA2472309C Multiple dose aromatase inhibitor for treating infertility
12/07/2010CA2471883C Phenylpyrimidine amines as ige inhibitors
12/07/2010CA2468542C Synthesis of 2-cyanoaziridine-1-carboxamide
12/07/2010CA2462637C Timed, sustained release multi-particulate dosage forms of propranolol
12/07/2010CA2461659C Modified release dosage forms
12/07/2010CA2460693C Alkyl urea retinoid agonists i
12/07/2010CA2456029C Stable emulsion composition
12/07/2010CA2453263C Pharmaceutical compositions containing terbinafine and use thereof
12/07/2010CA2446326C 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
12/07/2010CA2440111C Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
12/07/2010CA2436409C Kappa opioid receptor ligands
12/07/2010CA2434203C 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them and therapeutic use thereof
12/07/2010CA2427560C Alkynyl amides and their therapeutic applications
12/07/2010CA2425199C Formulation of substituted benzimidazoles
12/07/2010CA2421114C 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith
12/07/2010CA2417570C Tumor-specific t cell activation by peptide antigens
12/07/2010CA2406261C Antiinflammatory-containing plaster
12/07/2010CA2404767C Bile secretion promoting composition containing a 15-keto prostaglandin
12/07/2010CA2398335C Herpes virus strains
12/07/2010CA2394622C Stabilisation of pigments and polyunsaturated oils and oil concentrates
12/07/2010CA2383224C Extracts of orange peel for prevention and treatment of cancer
12/07/2010CA2381802C Synergistic combination of roflumilast and salmeterol
12/07/2010CA2375968C Imaging the dopamine transporter to determine ad-hd
12/07/2010CA2374995C Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
12/07/2010CA2368850C Methods for the prevention and/or the treatment of glutamate cytotoxicity
12/07/2010CA2367304C Cosmetic preparations comprising water-soluble .beta.-(1,3) glucans and desoxyribonucleic acids
12/07/2010CA2352094C High energy phototherapeutic agents
12/07/2010CA2328345C Process for the production of r-(+)-6-carboxamido-3-n-methylamino-1,2,3,4-tetrahydrocarbazole
12/07/2010CA2299632C Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors
12/07/2010CA2285516C Dopamine transporter imaging agents
12/07/2010CA2256543C Methods and compositions useful for inhibition of angiogenesis
12/07/2010CA2201368C Novel hormonal medicaments and use thereof for correcting oestrogen deficiencies
12/07/2010CA2153653C Growth differentiation factor-9
12/02/2010WO2010138955A2 Methods and compositions for treating neoplasia
12/02/2010WO2010138842A1 Ketal esters of anhydropentitols and uses thereof
12/02/2010WO2010138833A1 SUBSTITUTED IMIDAZO[1,5-a]QUINOXALINES AS INHIBITORS OF PHOSPHODIESTERASE 10
12/02/2010WO2010138823A1 Compositions and methods for inactivation of pathogens at genital tract surfaces
12/02/2010WO2010138820A2 N,n-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation
12/02/2010WO2010138802A2 Compositions and their use for removing cholesterol
12/02/2010WO2010138791A1 Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
12/02/2010WO2010138790A1 Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
12/02/2010WO2010138770A2 Methods for administration and formulations for the treatment of regional adipose tissue
12/02/2010WO2010138758A1 Methods for treating cancer and non-neoplastic conditions
12/02/2010WO2010138725A1 Treatment of pancreatic cancer using a dr5 agonist in combination with gemcitabine
12/02/2010WO2010138719A1 Polyal drug conjugates comprising variable rate-releasing linkers
12/02/2010WO2010138709A1 Anti-tnf induced apoptosis (atia) diagnostic markers and therapies
12/02/2010WO2010138706A1 Methods for treating breast cancer
12/02/2010WO2010138695A1 Methods for treating neurofibromatosis
12/02/2010WO2010138686A1 Mdri-inverse agents
12/02/2010WO2010138685A1 Methods for treating prostate conditions
12/02/2010WO2010138674A1 Azole antifungal compositions
12/02/2010WO2010138673A1 Inhibitors of c-met protein kinase
12/02/2010WO2010138670A2 Thiocolchicine derivatives, method of making and methods of use thereof
12/02/2010WO2010138666A1 Iap inhibitors
12/02/2010WO2010138665A1 Aminopyrazole triazolothiadiazole inhibitors of c-met protien kinase
12/02/2010WO2010138663A1 Substituted pyrazole inhibitors of c-met protein kinase
12/02/2010WO2010138660A1 Anticancer pharmaceutical formulation
12/02/2010WO2010138659A1 Methods for treating brain tumors
12/02/2010WO2010138652A1 Methods for treating kaposi sarcoma
12/02/2010WO2010138649A1 Oxazolidinone containing dimer compounds, compositions and methods to make and use
12/02/2010WO2010138644A1 Processes for the preparation of substituted tetrahydro beta-carbolines
12/02/2010WO2010138600A2 Pharmaceutical compositions for the treatment of pain
12/02/2010WO2010138598A2 Lxr modulators
12/02/2010WO2010138589A1 Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
12/02/2010WO2010138585A1 Pyrimidinones as pde10 inhibitors
12/02/2010WO2010138584A1 Beverage product with resveratrol
12/02/2010WO2010138578A1 Pyrimidine inhibitors of kinase activity
12/02/2010WO2010138577A1 Radiolabeled pde10 inhibitors
12/02/2010WO2010138576A1 Pyrimidine inhibitors of kinase activity
12/02/2010WO2010138575A1 Pyrimidine inhibitors of kinase activity
12/02/2010WO2010138535A1 Methods for treating type 2 diabetes in patients resistant to previous treatment with other anti-diabetic drugs employing an sglt2 inhibitor and compositions thereof
1 ... 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 ... 7860